AbbVie has spent years responding to a congressional probe over its drug pricing and patenting strategies, with the findings just becoming public late last month. Now, in a newly unveiled probe, congressional Democrats are zeroing in on the company’s tax payments. In a letter to CEO Richard Gonzalez dated Wednesday, Sen. Ron Wyden, D-Oregon, chairman of the Senate… Read More »
Drug pricing rhetoric has been quieted amid the COVID-19 pandemic and protests over racial justice, but President Donald Trump revived the topic on Friday. With four executive orders, the president pledged to lower prices through several previous policy proposals with months to go until the election. While Trump’s executive orders ran into immediate pushback from the drug industry, they won’t affect pricing all… Read More »
The Prescription Drug Pricing Act, penned by Senator Charles Grassley, R-Iowa, and co-sponsored by Senator Ron Wyden, D-Oregon, is in a weird state of limbo, sitting on the Senate’s legislative calendar for months. But if and when it ever passes, it could stand to save billions. Based on estimates from the Congressional Budget Office, the… Read More »
Dec. 13, 2019 — A U.S. House Democrat bill that would give Medicare the authority to negotiate prescription drug prices and provide new benefits for seniors was passed Thursday in a 230-192 vote along party lines. However, the bill has no chance of being passed by the Republican-controlled Senate and the White House has threatened… Read More »
We live in an incredible era of progress in human health. Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. With many of these new therapies we are no longer combating diseases over time, but potentially curing them in a single treatment. This is… Read More »